It's interesting to look at the strategy the company have taken...

It's interesting to look at the strategy the company have taken with 2591.

They've openly stated that they're concentrating on trof, sensible enough with limited resources. But imagine they went to Ph 1 with 2591 and it failed. There's a good chance that would kneecap the company, even though trof has had such good safety results. While I would love to see them push 2591, I can understand why they wouldn't.

I would imagine they would progess 2591 in a scenario where they were post deal and the Ph III trial was in progress or done.

So the strategy seems to be to push the business case, if you like, by pursuing patents.

It is interesting to speculate what they will do if they decide to push 2591. Given the preclinical work in FXS maybe they think that's the first target. Broad targets like "autism" are very hard to run trials for.